191 related articles for article (PubMed ID: 35116684)
1. Perioperative alectinib in a patient with locally advanced anaplastic lymphoma kinase positive non-small cell lung cancer (NSCLC): a case report.
Yue P; Zhang S; Zhou L; Xiang J; Zhao S; Chen X; Dong L; Yang W; Xiang Y
Transl Cancer Res; 2021 Aug; 10(8):3856-3863. PubMed ID: 35116684
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review.
Wang Z; Wu R; Li C; Cheng K; Di Y; Lv T; Liu H; Song Y
Anticancer Drugs; 2023 Nov; 34(10):1069-1075. PubMed ID: 36688904
[TBL] [Abstract][Full Text] [Related]
3. Pathological complete response to neoadjuvant alectinib in unresectable anaplastic lymphoma kinase positive non-small cell lung cancer: A case report.
Wang LM; Zhao P; Sun XQ; Yan F; Guo Q
World J Clin Cases; 2023 Aug; 11(22):5322-5328. PubMed ID: 37621597
[TBL] [Abstract][Full Text] [Related]
4. Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial.
Leonetti A; Minari R; Boni L; Gnetti L; Verzè M; Ventura L; Musini L; Tognetto M; Tiseo M
Clin Lung Cancer; 2021 Sep; 22(5):473-477. PubMed ID: 33762169
[TBL] [Abstract][Full Text] [Related]
5. Left total pneumonectomy performed after alectinib treatment for anaplastic lymphoma kinase-positive lung adenocarcinoma: a case report.
Wang Z; Shi Y; Zhang P; Chen Y
Chin Clin Oncol; 2023 Dec; 12(6):70. PubMed ID: 38195077
[TBL] [Abstract][Full Text] [Related]
6. Feasibility and Safety of Neoadjuvant Alectinib in Pulmonary Invasive Mucinous Adenocarcinoma with ALK Rearrangement: Case Report and Literature Review.
Gu R; Shi Z; Duan T; Song M
Onco Targets Ther; 2021; 14():5107-5113. PubMed ID: 34707369
[TBL] [Abstract][Full Text] [Related]
7. Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results.
Lococo F; Cancellieri A; Chiappetta M; Leonetti A; Cardillo G; Zanelli F; Mangiameli G; Toschi L; Guggino G; Romano FJ; Leuzzi G; Proto C; Spaggiari L; De Marinis F; Vita E; Ampollini L; Margaritora S; Tiseo M; Bria E
Clin Lung Cancer; 2023 Jul; 24(5):467-473. PubMed ID: 37061413
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer.
Hu Y; Ren S; Wang R; Han W; Xiao P; Wang L; Yu F; Liu W
Front Pharmacol; 2022; 13():816683. PubMed ID: 35873553
[No Abstract] [Full Text] [Related]
9. Case Report: ALK rearranged locally advanced lung adenocarcinoma showing inconsistent radiographic findings and pathological responses during neoadjuvant alectinib therapy.
Cao P; Zhao Q; Li Y; Shi R; Zhu G; Zhang Z; Zhang H; Liu M; Wei S; Liu H; Chen J
Front Pharmacol; 2023; 14():1140894. PubMed ID: 37663243
[TBL] [Abstract][Full Text] [Related]
10. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
[TBL] [Abstract][Full Text] [Related]
11. Successful salvage surgery followed by second ALK-TKI after alectinib failure in a patient with ALK-positive NSCLC.
Hashimoto H; Komori K; Kameda K; Taguchi S; Ozeki Y
Surg Case Rep; 2022 Apr; 8(1):59. PubMed ID: 35366157
[TBL] [Abstract][Full Text] [Related]
12. Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports.
Shi L; Gao S; Tong L; Meng Q; Zhou S; Yu D; Dong Y; Liu Z
Front Oncol; 2023; 13():1120511. PubMed ID: 37409244
[TBL] [Abstract][Full Text] [Related]
13. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
14. Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).
Popat S; Liu G; Lu S; Song G; Ma X; Yang JC
Future Oncol; 2021 Nov; 17(32):4237-4247. PubMed ID: 34423676
[TBL] [Abstract][Full Text] [Related]
15. Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung.
Imanishi N; Yoneda K; Taira A; Ichiki Y; Sato N; Hisaoka M; Tanaka F
Surg Case Rep; 2018 Mar; 4(1):19. PubMed ID: 29524063
[TBL] [Abstract][Full Text] [Related]
16. Perioperative crizotinib in a patient with stage IIIB ALK-positive non-small cell lung cancer: a case report.
Tian Y; Huang J; Li C; Jiang L; Lin H; Lu P; Luo Q; Yang G
Ann Transl Med; 2020 Jun; 8(12):770. PubMed ID: 32647695
[TBL] [Abstract][Full Text] [Related]
17. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Gadgeel SM
Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
[TBL] [Abstract][Full Text] [Related]
18. Alectinib Treatment of ALK Positive Non Small Cell Lung Cancer Patients with Brain Metastases: Our Clinical Experience.
Crvenkova S
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2020 Sep; 41(2):29-36. PubMed ID: 33011694
[TBL] [Abstract][Full Text] [Related]
19. Alectinib: A Review in Advanced, ALK-Positive NSCLC.
Paik J; Dhillon S
Drugs; 2018 Aug; 78(12):1247-1257. PubMed ID: 30030733
[TBL] [Abstract][Full Text] [Related]
20. Effect of alectinib versus crizotinib on progression-free survival, central nervous system efficacy and adverse events in ALK-positive non-small cell lung cancer: a systematic review and meta-analysis.
Yang YL; Xiang ZJ; Yang JH; Wang WJ; Xiang RL
Ann Palliat Med; 2020 Jul; 9(4):1782-1796. PubMed ID: 32527124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]